Odimma Therapeutics is pleased to announce its selection for the France 2030 Export Program, a national initiative supporting high-potential French innovators in their international development.
This recognition marks an important milestone for Odimma as the company prepares the entry into clinics of ODI-2001, its next-generation personalized cancer immunotherapy platform. The program will provide dedicated support to strengthen international visibility, expand strategic partnerships, and facilitate R&D.
“Being selected for the France 2030 Export Program is both an honour and a strong signal for the Company,” said Jean-Marc Limacher, Chairman and Chief Medical Officer of Odimma Therapeutics. “This initiative will help us advance our clinical roadmap as we transition toward first-in-human studies and further engage with international collaborators.”
Participation in the France 2030 Export Program aligns with Odimma’s mission to deliver innovative, patient-tailored immunotherapies and reinforces the company’s commitment to building a globally competitive biotechnology platform.
For more information, please contact:
contact@odimma-therapeutics.